<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400438</url>
  </required_header>
  <id_info>
    <org_study_id>HER-ception</org_study_id>
    <nct_id>NCT01400438</nct_id>
  </id_info>
  <brief_title>Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer</brief_title>
  <acronym>HER-ception</acronym>
  <official_title>Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer: Fatigue and Quality of Life During and Waning of Treatment, Psychosocial Aspects (Environment, Work)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies have been devoted to the quality of life of patients during adjuvant&#xD;
      chemotherapy for breast cancer by highlighting fatigue, psychological distress and impact on&#xD;
      the immediate environment (spouse, children) during this difficult time for women. Curiously,&#xD;
      no study to date has been submitted or published about how women with a one-year treatment&#xD;
      &quot;extra&quot; Herceptin ® live this period in terms of quality of life, in terms of psychological&#xD;
      impact for themselves and their families.&#xD;
&#xD;
      The investigators have no more data on how often they return to work during this treatment or&#xD;
      on the psycho-social parameters which underpin them. It therefore seemed interesting to &quot;give&#xD;
      a spotlight&quot; on this particular period in these women HER2 + by comparing a patient&#xD;
      population of same age receiving the same adjuvant but with no Herceptin ®.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>score of fatigue</measure>
    <time_frame>at 9 months</time_frame>
    <description>The main objective of this study is to evaluate the score of fatigue in patients with HER2 overexpressing breast cancer and for whom Herceptin ® treatment is prescribed, compared with a population of patients treated with the same age the same chemotherapy without Herceptin ®.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the quality of life</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <description>Assess the quality of life of patients treated for breast cancer with surgery followed by adjuvant chemotherapy (+/-hormonotherapy) associated with treatment with Herceptin ®, compared with patients of similar age treated with the same chemotherapy without Herceptin ®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Herceptin ® in the professional lives</measure>
    <time_frame>at 3, 6 ,9 and 12 months</time_frame>
    <description>Assess the impact of Herceptin ® in the professional lives of patients, compared to patients not treated with Herceptin ®.&#xD;
Evaluation done by a specific questionnaire on professional lives, a scoring will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantitative and qualitative psychological impact of Herceptin ®</measure>
    <time_frame>at 3 months</time_frame>
    <description>Assess the quantitative and qualitative psychological impact of Herceptin ® in patients so treated, compared to patients not treated with Herceptin ®.&#xD;
Evaluation done by specific questionnaires, a scoring will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>a qualitative sociological analysis among spouses of patients</measure>
    <time_frame>at 6 months</time_frame>
    <description>Conduct a qualitative sociological analysis among spouses of patients treated with Herceptin ®.&#xD;
An interview with a sociologist will be done and characteristic sociologic of patients will be described.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>patients group with Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients beginning Herceptin in adjuvant after chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient not beginning Herceptin after chemotherapy : control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <description>delivery of questionnaires and self-psychological interview</description>
    <arm_group_label>patients group with Herceptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <description>delivery of questionnaires and self-psychological interview</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged over 18&#xD;
&#xD;
          -  Invasive breast carcinoma confirmed histologically&#xD;
&#xD;
          -  Non-metastatic cancer&#xD;
&#xD;
          -  Surgery of the primary tumor performed (mastectomy or lumpectomy) and associated with&#xD;
             an audit axillary (sentinel node and / or axillary dissection)&#xD;
&#xD;
          -  Patient should receive their last course of adjuvant chemotherapy (3 FEC and 3&#xD;
             Taxotere)&#xD;
&#xD;
          -  Patients not receiving the third course of Taxotere because of toxicities may be&#xD;
             included in the fifth course of chemotherapy is the second of Taxotere&#xD;
&#xD;
          -  For the group Herceptin ®: HER2 overexpression without contraindication to treatment&#xD;
             administration&#xD;
&#xD;
          -  For the control group: no indication for Herceptin ®&#xD;
&#xD;
          -  Radiation therapy and / or adjuvant hormonal therapy allowed&#xD;
&#xD;
          -  Free and informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women under 18 or over 60 years&#xD;
&#xD;
          -  Histology other than adenocarcinoma&#xD;
&#xD;
          -  Metastatic Breast Cancer&#xD;
&#xD;
          -  Chemotherapy neoadjuvant&#xD;
&#xD;
          -  Surgery of the primary tumor unrealized&#xD;
&#xD;
          -  Lack of adjuvant chemotherapy with Taxotere 3 FEC and 3&#xD;
&#xD;
          -  Patients with a history of malignancy within 5 years, outside of a basal cell cancer&#xD;
             or cancer of the cervix treated and cured&#xD;
&#xD;
          -  Patient under guardianship or unable to give informed consent,&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Patient unable to undergo a medical for geographical, social or psychopathological&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne DELCAMBRE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herceptin</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Quality of life</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

